Candel Therapeutics, Inc. CADL

11.02 (0.53) (4.59%) as of 25 Sep
Market cap
$883.8M
P/E
0.0×
Insider Buys alert about insiders buying in the last 12 month
Dec '17 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
P/E ratio
— 0.00 0.00 0.00 0.00 — — —
P/S ratio
— 661.64 661.64 1,180.70 408.14 — — —
P/FCF ratio
— 0.00 0.00 0.00 0.00 — — —
P/Operating CF
— (18.40) (18.40) (28.18) (7.41) — — —
P/B ratio
— 0.00 0.00 2.30 1.07 — — —
Price to Tangible BV
— 0.00 0.00 2.30 1.07 — — —
EV/Sales
— 473.49 473.49 527.76 18.19 — — —
EV/EBITDA
— 0.00 0.00 0.00 0.00 — — —
EV/Operating CF
— (3.91) (3.91) (2.97) (0.07) — — —
EV/FCF
— (3.43) (3.43) (2.74) (0.07) — — —
Quick Ratio
— 31.96 7.44 15.41 12.48 2.50 2.74 13.31
Current Ratio
— 32.06 7.46 15.84 12.81 2.59 2.77 13.49
Net Debt/EBITDA
— 4.96 2.49 3.22 1.44 0.38 2.78 1.53
Debt/Assets
0.00% 0.92% 2.47% 0.63% 27.43% 51.64% 11.70% 37.65%
Debt/Equity
— 0.01 (0.04) 0.01 0.45 1.67 0.19 0.91
Asset Turnover
— 0.01 0.00 0.00 0.00 0.00 0.00 0.00
Operating CF/Net income
— 0.63 0.51 0.62 1.67 0.90 0.49 1.00
Capex/Depreciation
— 0.00 (16.22) (7.91) (1.67) (0.29) (0.02) (0.66)
Interest Coverage
— 0.00 0.00 0.00 0.00 0.00 0.00 0.00
ROE
— 52.15% 111.90% (178.06%) (33.61%) (125.50%) (139.56%) (64.58%)
ROA
— (35.90%) (42.00%) (56.67%) (22.52%) (63.82%) (74.53%) (32.91%)
ROIC
— 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
— (18.63%) (53.22%) (43.30%) (26.56%) (146.94%) (80.59%) (33.48%)
Average Days of Receivables
— 0.00 0.00 0.00 0.00 — — —
Research and Development Expense of Revenue
— 5,251.20% 7,003.20% 12,142.40% 16,629.60% 0.00% 0.00% 0.00%
Selling, General and Administrative Expense of Revenue
— 2,044.00% 4,144.80% 8,538.40% 11,248.00% 0.00% 0.00% 0.00%
Intangible Assets out of Total Assets
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Share Based Compensation of Revenue
— 0.00% 1,685.60% 2,370.40% 1,845.60% 0.00% 0.00% 0.00%
Graham Net Nets
— (0.60) (0.60) 0.41 0.82 — — —
Graham Number
— 0.00 0.00 0.00 0.00 — — —
Earnings Yield
— (33.03%) (33.03%) (31.64%) (36.72%) — — —
Free Cash Flow Yield
— (20.87%) (20.87%) (16.30%) (64.13%) — — —
Revenue per Share
— 0.00 0.01 0.01 0.00 0.00 0.00 0.00
Operating CF per Share
— (0.18) (0.78) (1.18) (1.09) (1.18) (0.85) (0.72)
Capex per Share
— 0.00 (0.13) (0.10) (0.04) (0.01) 0.00 (0.01)
Free Cash Flow per Share
— (0.18) (0.91) (1.27) (1.13) (1.19) (0.85) (0.73)
Cash per Share
— 1.55 3.02 4.38 2.43 1.22 3.24 2.26
Shareholders Equity per Share
— 1.41 (2.03) 3.40 1.66 0.44 2.09 0.98
Interest Debt per Share
— 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
— 1.41 (2.03) 3.40 1.66 0.44 2.09 0.98
Free Cash Flow
— (5.18) (10.55) (24.05) (32.72) (34.52) (27.04) (38.87)
Working Capital
— 43.80 30.43 79.58 66.33 22.61 66.28 112.39
Capital Expenditures
— (0.16) (1.48) (1.83) (1.30) (0.28) (0.02) (0.56)
Net Current Asset Value
— 40.33 (26.70) 59.88 41.97 8.34 63.27 48.12
EV/EBIT
— 0.00 0.00 0.00 0.00 — — —
Capex to Sales
— 0.00 11.81 14.68 10.38 0.00 0.00 0.00
Net Profit Margin
— (6,592.00%) (14,144.00%) (28,899.20%) (15,035.20%) 0.00% 0.00% 0.00%
Price to Operating Income
— 0.00 0.00 0.00 0.00 — — —
Other line items
Depreciation/Fixed assets
— 0.10 0.03 0.06 0.18 0.30 0.45 0.51
Cash ROIC
— (6.48%) (95.34%) (17.68%) (25.77%) (53.94%) (16.10%) (18.26%)
Accounts Receivable Turnover
— 0.00 0.00 0.00 0.00 — — —
Accounts Payable Turnover
— 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
— — — 0.00 0.00 — — —
Average Days of Payables
— 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days of Inventory on Hand
— — — 0.00 0.00 — — —
Average Payables
— 0.57 0.57 1.26 0.99 0.40 0.33 0.68
Average Assets
— 22.95 42.09 63.74 83.45 59.45 74.03 116.03
Average Common Equity
— (15.80) (15.80) 20.29 55.93 30.23 39.54 59.12

Fold the line items

Columns are period end dates